Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Receives Consensus Rating of “Buy” from Brokerages
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has been given a consensus rating of “Buy” by the nine brokerages that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $14.67.
Several analysts have issued reports on the stock. Stifel Nicolaus restated a “buy” rating and set a $10.00 price target on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. Aegis restated a “buy” rating and set a $11.00 price target on shares of Conatus Pharmaceuticals in a research report on Monday, May 15th. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. ValuEngine upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 24th. Finally, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Conatus Pharmaceuticals in a research report on Thursday, June 29th.
Several hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC raised its stake in Conatus Pharmaceuticals by 193.5% in the fourth quarter. Renaissance Technologies LLC now owns 183,700 shares of the biotechnology company’s stock worth $968,000 after buying an additional 121,100 shares in the last quarter. Nationwide Fund Advisors purchased a new stake in Conatus Pharmaceuticals during the first quarter worth $413,000. Acadian Asset Management LLC purchased a new stake in Conatus Pharmaceuticals during the first quarter worth $854,000. Bank of New York Mellon Corp raised its stake in Conatus Pharmaceuticals by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company’s stock worth $464,000 after buying an additional 1,655 shares in the last quarter. Finally, Courage Capital Management LLC raised its stake in Conatus Pharmaceuticals by 25.0% in the first quarter. Courage Capital Management LLC now owns 125,000 shares of the biotechnology company’s stock worth $721,000 after buying an additional 25,000 shares in the last quarter. Institutional investors own 22.53% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Receives Consensus Rating of “Buy” from Brokerages” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/12/conatus-pharmaceuticals-inc-nasdaqcnat-receives-consensus-rating-of-buy-from-brokerages.html.
Conatus Pharmaceuticals (CNAT) opened at 5.24 on Friday. The firm’s 50-day moving average price is $5.88 and its 200 day moving average price is $5.61. Conatus Pharmaceuticals has a one year low of $1.45 and a one year high of $9.40. The firm’s market capitalization is $157.22 million.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. The business had revenue of $10 million for the quarter, compared to analyst estimates of $9.33 million. During the same period last year, the firm posted ($0.30) EPS. On average, equities analysts anticipate that Conatus Pharmaceuticals will post ($0.45) earnings per share for the current fiscal year.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.